82 FR 10778 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 30 (February 15, 2017)

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10778-10779]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for

[[Page 10779]]

licensing to achieve expeditious commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Synergistic Internal Ribosomal Entry Site (IRES)--MicroRNA-Based 
Approach for Attenuation of Flaviviruses and Live Vaccine Development

    Description of Technology: Many members of the Flaviviridae family 
are emerging and reemerging human pathogens that have caused outbreaks 
of devastating and often fatal diseases and represent a serious public 
health problem on a global scale. There is no single attenuation 
strategy that exists which is sufficient to prepare a safe, efficacious 
and immunogenic live attenuated virus vaccine that will work 
universally for Flaviviridae. This patent application claims live 
attenuated flavivirus vaccines, live attenuated multivalent flavivirus 
vaccines, and methods of preventing flavivirus infections as well as 
methods of making the vaccines claimed in the application. More 
specifically, this patent application claims methods for attenuating a 
flavivirus or chimeric flavivirus using a synergistic dual strategy 
involving inserting miRNA-targeting sequences to restrict virus 
replication in target hosts, cells and/or tissues and placing one or 
more flavivirus genes under translational control of an internal 
ribosomal entry site (IRES).
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Diagnostics
 Vaccines

    Competitive Advantages:
 Potential one-dose flavivirus vaccine
 Ease of manufacture in Vero cells
 Low-cost potential vaccine
 Developing and developed world potential vaccines

    Development Stage:

 In vivo data available (animal)

    Inventors: Alexander Pletnev (NIAID), Konstantin Tsetsarkin 
(NIAID).
    Intellectual Property: HHS Reference No. E-006-2017/0--U.S. 
Provisional Application No. 62/443,214, filed January 6, 2017.
    Licensing Contact: Peter Soukas, J.D., 301-594-8730; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize vaccine(s) for prophylaxis against 
flavivirus infections. For collaboration opportunities, please contact 
Peter Soukas, J.D., 301-594-8730; [email protected].

    Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03017 Filed 2-14-17; 8:45 am]
 BILLING CODE 4140-01-P